Lantheus Holdings, Inc. Share Price & Technical Analysis

LNTH · $103.0 (+9.03%)

Healthcare / Drug Manufacturers - Specialty & Generic

AI Score 76 · Bullish

$103.0

+9.03%

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceuti

Price chart

Seasonality

May has 4 positive and 1 negative years (last 5 years shown)

21% return in May, -1% avg return in past 3 year May month.

46% return in 2026, 22% avg return in past 3 years.

Swipe sideways to see all months →

JanFebMarAprMayJunJulAugSepOctNovDecYr
260%12%2%11%21%46%
253%4%5%7%-28%9%-12%-22%-6%13%2%14%-11%
24-16%25%-5%7%24%-3%31%2%3%0%-19%-1%48%
2312%28%12%4%2%-4%3%-21%1%-7%11%-13%28%
22-12%87%18%20%2%-6%17%3%-10%5%-17%-19%89%

Monthly return % by calendar month · historical pattern, not a forecast

AI snapshotScore 76/100

Bullish · Strong · Strong

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Full AI Q&A, portfolio tracking, and live alerts in the app.

Key metrics

Market cap

$6.09B

P/E ratio

22.31

52W high

$103.9

52W low

$47.25

Volume

20,20,676

Beta

-0.08

Related stocks in Healthcare

Frequently asked questions

What is Lantheus Holdings, Inc. share price today?
Lantheus Holdings, Inc. (LNTH) last traded around $103.0 on StockPro. Prices refresh every few minutes during market hours.
What technical signals does LNTH have?
StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LNTH. Download the app for real-time alerts.
How can I analyze Lantheus Holdings, Inc. stock?
Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.

Explore more on StockPro